Literature DB >> 20473499

Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series.

Luca Cantarini1, Orso Maria Lucherini, Rolando Cimaz, Donato Rigante, Cosima Tatiana Baldari, Franco Laghi Pasini, Mauro Galeazzi.   

Abstract

Tumor necrosis factor receptor-1-associated periodic syndrome (TRAPS) is the most common autosomal dominant autoinflammatory disorder and is caused by mutations in the TNFRSF1A gene encoding the 55-kDa receptor for tumor necrosis factor (TNF)-α. TRAPS is characterized by recurrent attacks of fever, typically lasting from 1 to 3 weeks. In addition to fever, common clinical features include periorbital edema, a migratory erythematous plaque simulating erysipela with underlying myalgia, and arthralgia or arthritis. Serosal membrane inflammation is also a common feature, usually in the form of polyserositis. To date, at least 40 different TNFRSF1A mutations have been identified, but few patients with symptoms highly suggestive of TRAPS with no mutations in the TNFRSF1A gene have recently been described, thus suggesting that not all mutations are yet known or that alternative mechanisms might be involved in the pathogenesis of the disease. We report on three such patients here.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473499     DOI: 10.1007/s00296-010-1512-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  15 in total

1.  Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.

Authors:  M F McDermott; I Aksentijevich; J Galon; E M McDermott; B W Ogunkolade; M Centola; E Mansfield; M Gadina; L Karenko; T Pettersson; J McCarthy; D M Frucht; M Aringer; Y Torosyan; A M Teppo; M Wilson; H M Karaarslan; Y Wan; I Todd; G Wood; R Schlimgen; T R Kumarajeewa; S M Cooper; J P Vella; C I Amos; J Mulley; K A Quane; M G Molloy; A Ranki; R J Powell; G A Hitman; J J O'Shea; D L Kastner
Journal:  Cell       Date:  1999-04-02       Impact factor: 41.582

2.  A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling.

Authors:  F K Chan; H J Chun; L Zheng; R M Siegel; K L Bui; M J Lenardo
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

Review 3.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

4.  A novel missense mutation (C30S) in the gene encoding tumor necrosis factor receptor 1 linked to autosomal-dominant recurrent fever with localized myositis in a French family.

Authors:  C Dodé; T Papo; C Fieschi; C Pêcheux; E Dion; F Picard; P Godeau; J Bienvenu; J C Piette; M Delpech; G Grateau
Journal:  Arthritis Rheum       Date:  2000-07

5.  Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications.

Authors:  Andrea D'Osualdo; Francesca Ferlito; Ignazia Prigione; Laura Obici; Antonella Meini; Francesco Zulian; Alessandra Pontillo; Fabrizia Corona; Roberto Barcellona; Marco Di Duca; Giuseppe Santamaria; Francesco Traverso; Paolo Picco; Maurizia Baldi; Alessandro Plebani; Roberto Ravazzolo; Isabella Ceccherini; Alberto Martini; Marco Gattorno
Journal:  Arthritis Rheum       Date:  2006-03

6.  The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Catherine Dodé; Marc André; Thierry Bienvenu; Pierre Hausfater; Christophe Pêcheux; Jacques Bienvenu; Jean-Claude Lecron; Philippe Reinert; Daniel Cattan; Jean-Charles Piette; Marie-France Szajnert; Marc Delpech; Gilles Grateau
Journal:  Arthritis Rheum       Date:  2002-08

7.  Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Belinda Nedjai; Graham A Hitman; Niamh Quillinan; Robert J Coughlan; Leigh Church; Michael F McDermott; Mark D Turner
Journal:  Arthritis Rheum       Date:  2009-02

8.  Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation.

Authors:  D W Banner; A D'Arcy; W Janes; R Gentz; H J Schoenfeld; C Broger; H Loetscher; W Lesslauer
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

9.  Infevers: an evolving mutation database for auto-inflammatory syndromes.

Authors:  Isabelle Touitou; Suzanne Lesage; Michael McDermott; Laurence Cuisset; Hal Hoffman; Catherine Dode; Nitza Shoham; Ebun Aganna; Jean-Pierre Hugot; Carol Wise; Hans Waterham; Denis Pugnere; Jacques Demaille; Cyril Sarrauste de Menthiere
Journal:  Hum Mutat       Date:  2004-09       Impact factor: 4.878

10.  Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Belinda Nedjai; Graham A Hitman; Nasim Yousaf; Yuti Chernajovsky; Susanna Stjernberg-Salmela; Tom Pettersson; Annamari Ranki; Philip N Hawkins; Peter D Arkwright; Michael F McDermott; Mark D Turner
Journal:  Arthritis Rheum       Date:  2008-01
View more
  7 in total

Review 1.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 2.  Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Donato Rigante; Giuseppe Lopalco; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Giacomo Emmi; Luisa Costa; Elena Silvestri; Laura Andreozzi; Florenzo Iannone; Mauro Galeazzi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2014-06-17       Impact factor: 2.980

Review 3.  Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens.

Authors:  Marco Cattalini; Martina Soliani; Giuseppe Lopalco; Donato Rigante; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2016-05-25       Impact factor: 3.397

Review 4.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 5.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711

6.  First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS).

Authors:  Orso Maria Lucherini; Laura Obici; Manuela Ferracin; Valerio Fulci; Michael F McDermott; Giampaolo Merlini; Isabella Muscari; Flora Magnotti; Laura J Dickie; Mauro Galeazzi; Massimo Negrini; Cosima Tatiana Baldari; Rolando Cimaz; Luca Cantarini
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

Review 7.  Anakinra Therapy for Non-cancer Inflammatory Diseases.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.